Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Xpeng Inc - ADR — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Xpeng Inc - ADR trades at $9.51 (market cap $9.24B). The key difference: Xpeng Inc - ADR is far larger — about 9.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Xpeng Inc - ADR for 81 Days on average.
| MRVI | XPEV | |
|---|---|---|
Market Cap | $972.90M | $9.24B |
Volume | 4,325,710 | 6,669,510 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $28.07 |
52-Week Low | $2.83 | $9.25 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $1.08B | $11.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
XPeng (XPEV) trades at $9.42, down 2.48% amid bearish technical signals despite strong revenue growth. The company delivered 41,256 vehicles in September 2026 and is expanding globally with new model launches. While revenue surged to $76.72 billion in 2025, net losses persist at -$1.14 billion, though margins are improving. Analyst consensus remains bullish with a $17.55 price target.
Investment outlook balances growth potential against profitability challenges. XPeng's expansion into AI robotics and European markets offers upside, but persistent losses and competitive pressures pose risks. The stock presents a speculative opportunity for investors betting on future profitability and market share gains in the evolving EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
